JAGSNPHARM vs NGLFINE: Stock Comparison
NGL FINE CHEM is the larger company by market capitalisation. JAGSONPAL PHARMACEUTICALS shows a higher ROE, a higher dividend yield and lower leverage, while NGL FINE CHEM shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
JAGSNPHARM leads 6; NGLFINE leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | JAGSNPHARM | NGLFINE |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | JAGSNPHARM | NGLFINE |
|---|---|---|
| Live Price | ₹210.86 | ₹2,646.5 |
| Day Change | -3.24% | 0.88% |
| Volume | 65,521 | 71,200 |
| 52-Week High | ₹264.5 | ₹3,602 |
| 52-Week Low | ₹155 | ₹1,271 |
| Distance from 52W High | -20.28% | -26.53% |
Valuation
| Metric | JAGSNPHARM | NGLFINE |
|---|---|---|
| Market Cap | ₹1,393 Cr | ₹1,616 Cr |
| P/E Ratio | 30.83x | 28.25x |
| P/B Ratio | 5.11x | 4.91x |
| EPS | ₹2 | ₹29.78 |
| Book Value | ₹41.95 | ₹532.9 |
| Dividend Yield | 1.84% | 0.07% |
Growth
| Metric | JAGSNPHARM | NGLFINE |
|---|---|---|
| Revenue Growth (TTM YoY) | 9.6% | 57.2% |
| EPS Growth (TTM YoY) | 23.8% | 1,539.8% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | JAGSNPHARM | NGLFINE |
|---|---|---|
| ROE | 15.6% | 13.01% |
| ROCE | 16.4% | 10.55% |
| Net Margin | 15% | 9.59% |
| Operating Margin | 20.38% | 12.08% |
| Debt to Equity | 0x | 0.34x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | JAGSNPHARM | NGLFINE |
|---|---|---|
| Promoter Holding | 25.55%▲ 0.43 pp | 72.49% |
| FII Holding | 2.3%▼ 0.14 pp | 0.04%▼ 0.01 pp |
| DII Holding | 0.62%▲ 0.4 pp | 0%▼ 0.02 pp |
| Public Holding | 28.03%▼ 1.42 pp | 27.46%▲ 0.03 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: JAGSONPAL PHARMACEUTICALS and NGL FINE CHEM.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.